The global schizoaffective disorders treatment market is expected to experience an upsurge due to rising torpid lifestyle, increasing healthcare spending and awareness, prevalence of chronic diseases, the new drugs in pipeline in the mental health sector, and availability of advanced healthcare treatment. According to the National Institute of Mental Health (NIMH) survey, 61.5 million American adults are diagnosed with a mental health disorder. Out of 119 total medicines in pipeline, 36 are for schizophrenia. New Medications in Depression and Schizophrenia (NEWMEDS), a Europe-based foundation is an international industry–academic collaboration, which helps in finding new methods and in decreasing the clinical trial time.
The schizoaffective disorders treatment market can be segmented on the basis of type, treatment, and cause of disorder. Types of schizoaffective disorders include manic type (symptoms of schizophrenia and mania together when unwell), depressive type (symptoms of schizophrenia and depression together when unwell), mixed type (symptoms of schizophrenia, mania, and depression together when unwell), and schizoaffective disorders (symptoms of schizoaffective psychosis when unwell). On the basis of treatment, the schizoaffective market is sub-divided as antipsychotics (clozapine, risperidone, haloperidone, and olanzapine), mood stabilizers (lithium and divalproex), anticonvulsants (carbamazepine and valproate), antidepressants (citalopram, fluoxetine, and escitalopram), and psychotherapy (psychotherapy and counseling, family or group therapy). On the basis of causes, they are classified as genetic factors (schizoaffective disorders have more prevalence in families, where other members have schizophrenia, schizoaffective disorders or bipolar disorders), chemical factors (imbalance in chemical composition which are the neurotransmitters), and environmental factors (stress and lifestyle disorders).
Usually, the treatment is a combination of antipsychotic medication, mood stabilizers, antidepressant medication, and talking therapies. National Institute for Health and Care Excellence (NICE) has guidelines as to how Northern Hospital Services (NHS) should treat health conditions. Average person minimal chances of 1 in 100 can be increased to 1 in 4 by some genetic mutation in 22q11 gene. Currently, the treatment covers decreasing incidence of hallucinations and paranoia. However, there is a huge untapped market in the treatment of cognitive problems and social difficulties caused by disorders. The COGNITIV clinical trial program is working on Encenicline, which is expected to improve the cognitive impairment issues. Even, Nuplazid, an Aciadia Pharmaceutical product, is under trial to help to extend the current antipsychotic treatment. A new class of therapy is trying to breakthrough called the intra-cellular therapy, which instead of working outside the neuron would go deep inside them.
Region-wise schizoaffective disorders treatment market is prevalent in North America, Europe, and Asia Pacific. In case of North America and Europe, the success factors, which have led them to lead in this market are availability of well-structured regulatory framework, availability of advanced healthcare facilities, higher rates of practicing defined regulatory framework, higher rates of awareness about growth disorders, and reimbursement coverage. Rapidly improving healthcare infrastructure, swift growth of the medical tourism industry in Asia Pacific, government initiatives to strengthen healthcare and biotechnology sectors, rising disposable incomes, availability of advanced healthcare facilities and rising awareness about healthcare facilities, and increasing healthcare spending are the factors contributing to the presence of this market in Europe. In the Asia Pacific market, India and China are expected to be booming markets due to strong presence of medical tourism. The WHO 2013 report states that out of 100% international inpatients receiving care, 35% to 0% are medical travelers. The main drivers of medical tourism are advanced technology, quicker access for medically necessary procedures, and better-quality care for medically necessary procedures, lower-cost care for discretionary procedures, and medically necessary procedures. Centers for Disease Control and Prevention (CDC) estimated 750,000 U.S. residents travelling abroad each year for surgeries or medical treatment.
Some key players of the schizoaffective disorders treatment market are Merz Pharma GmbH & Co., Eli Lilly and Company, KGaA, Ciba Pharmaceuticals, Elan Pharmaceuticals, Janssen-Cilag Pty Limited, AstraZeneca PLC, and Abbott Pharmaceuticals. Abbott has a new compound in pipeline called the ABT-126 for treatment of cognitive impairment. The European Union has approved the first and only antipsychotic treatment called INVEGA; the decision was supported by Committee for Medicinal Products for Human Use (CHMP). Janssen Pharma’s Invega Sustenna, a new supplement that is once-a-month therapy for schizoaffective disorders has been approved by the U.S. Food and Drug Administration (FDA). All these development is expected to further propel the growth of the schizoaffective disorders treatment market.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.